Aclacinomycin A



BML-AW8655-0005	5 mg	76.00 USD

Originally identified as an anti-tumor drug, aclacinomycin A is the first described non-peptidic inhibitor showing discrete specificity for the chymotrypsin-like activity of the 20S proteasome. Aclacinomycin A has no effect on cathepsin B, it stimulates trypsin activity but inhibits the activity of both chymotrypsin and calpain.

Product Specification

Alternative Name:	Aclarubicin

Formula:	C₄₂H₅₃NO₁₅

MW:	811.9

Purity:	≥95% (TLC)

Appearance:	Yellow powder with orange cast

CAS:	57576-44-0

Solubility:	Soluble in DMSO (25mg/ml) or dimethyl formamide (25mg/ml)

Long Term Storage:	-20°C

Background / Technical Information:	Please click here for the comprehensive product datasheet.

Please mouse over

Product Literature References

The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome: M. E. Figueiroda-Pereira et al.; J. Biol. Chem. 271, 16455 (1996), Abstract;

Inhibition of different steps of the ubiquitin system by cisplatin and aclarubicin: T. Isoe et al.; Biochim. Biophys. Acta. 1117, 131 (1992), Abstract;